Article and Video CATEGORIES

Cancer Journey

Search By

Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?
Tue, 12/08/2015 - 06:00
GRACE Videos and Articles



Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.


Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.



Dr. West:  So let’s turn to the question of — you have agents like these third-generation EGFR inhibitors that have impressive activity in patients with acquired resistance after a prior, say, first-generation EGFR inhibitor like Iressa (gefitinib), Tarceva (erlotinib), or the second-generation inhibitor Gilotrif (afatinib). Those agents really have activity that seems limited to the first line setting, not much activity in acquired resistance. There’s going to be a temptation to move these later agents into the first line setting with the thought that maybe you can postpone, for much longer, acquired resistance — there’s certainly trials looking at this, but before we have the result of those trials, is that going to be something that you’re going to be tempted to do or recommend?

Dr. Horn:  Not unless I have a patient who maybe has a germline T790m mutation, so T790m at the time of diagnosis. I think that those trials need to come out and we need to see what the combined progression-free survival is, just of third-generation on its own, compared to progression-free survival with a first, followed by a third, and without that data, I’m not tempted to change my practice at this time.

Dr. West:  Ben, what do you think?

Dr. Solomon:  Yeah, I’m with Leora. I think they’re really important trials, the trials with both compounds in the first line, compared with first-generation inhibitors — and I guess the rationale is that you might be able to prevent and delay the emergence of resistance by targeting T790 right from the beginning, but we know resistance develops to these third-generation inhibitors. As well, they’re new mutations that prevent the third-generation inhibitors from binding to the EGFR, and it might be that you may not be able to rescue and make the tumor re-respond to another EGFR inhibitor later on down the track, so I don’t think we can presuppose the answer to these trials, but I think they’re important, and certainly, if the time that you can control the disease by using a third-generation inhibitor first is longer than you can by using a first-generation inhibitor, followed by a third-generation inhibitor, it’s going to change the way we all practice.

Dr. West:  Well, that’s a good point though, that these are all looking at progression-free survival as the primary endpoint, but that’s not really the key issue — it’s not whether a first-generation agent is less than a third-generation agent, as much as first-generation, followed by the third-generation, versus starting with the third-generation, because your goal isn’t just to get them to this coming Christmas, but have patients live many Christmases in the future, and, so, I think that, to me, seeing if it changes overall survival, or really, looking further beyond just one line of therapy is an important issue.

Next Previous link

Previous PostNext Post

Related Content

Mandarin LCVL
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit:…;  
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Blood Cancer OncTalk
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29